Ridgway L E, Muise K, Wright J W, Patterson R M, Newton E R
Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio 78284-7836.
Am J Obstet Gynecol. 1990 Sep;163(3):879-82. doi: 10.1016/0002-9378(90)91087-s.
We compared oral magnesium oxide with oral terbutaline sulfate in a prospective, randomized manner to determine efficacy and side effects. Preterm labor patients whose labor was arrested with parenteral tocolysis were randomized to oral tocolysis with either magnesium oxide, 200 mg every 3 to 4 hours (n = 23), or terbutaline, 2.5 to 5 mg every 3 to 4 hours (n = 27). The number of patients who were delivered of infants before 36 weeks' gestation was similar between groups (18.5% receiving terbutaline versus 17.4% receiving magnesium). At least one side effect occurred in 81.5% of patients in the terbutaline group and 47.8% in the magnesium group (p less than 0.01). Finally, the cost for 1 day of magnesium (20 cents) is approximately one third the cost of terbutaline (56 cents). These data suggest that oral magnesium oxide is as effective as terbutaline for the maintenance of tocolysis, with fewer side effects and at a lower cost.
我们以前瞻性、随机的方式比较了口服氧化镁与口服硫酸特布他林的疗效和副作用。将经胃肠外宫缩抑制剂抑制宫缩的早产患者随机分为口服氧化镁组（每3至4小时服用200毫克，共23例）或特布他林组（每3至4小时服用2.5至5毫克，共27例）进行口服宫缩抑制治疗。两组在妊娠36周前分娩的患者数量相似（接受特布他林治疗的为18.5%，接受氧化镁治疗的为17.4%）。特布他林组81.5%的患者至少出现了一种副作用，氧化镁组为47.8%（p小于0.01）。最后，1天的氧化镁费用（20美分）约为特布他林费用（56美分）的三分之一。这些数据表明，口服氧化镁在维持宫缩抑制方面与特布他林同样有效，副作用更少且成本更低。
